Cargando…

Aspirin for Prevention of Cardiovascular Disease

We used data from the 2013 Mississippi Behavioral Risk Factor Surveillance System to examine aspirin use for the prevention of primary and secondary cardiovascular disease (CVD), based on the 2009 US Preventive Services Task Force (USPSTF) guidelines, among Mississippi men (aged 45–79 y) and women (...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendy, Vincent L., Vargas, Rodolfo, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590489/
https://www.ncbi.nlm.nih.gov/pubmed/28880838
http://dx.doi.org/10.5888/pcd14.170171
_version_ 1783262551279140864
author Mendy, Vincent L.
Vargas, Rodolfo
Zhang, Lei
author_facet Mendy, Vincent L.
Vargas, Rodolfo
Zhang, Lei
author_sort Mendy, Vincent L.
collection PubMed
description We used data from the 2013 Mississippi Behavioral Risk Factor Surveillance System to examine aspirin use for the prevention of primary and secondary cardiovascular disease (CVD), based on the 2009 US Preventive Services Task Force (USPSTF) guidelines, among Mississippi men (aged 45–79 y) and women (aged 55–79 y) and to explore differences in aspirin use by sociodemographic characteristics. Among those without CVD, 39.1% of men and 45.9% of women reported taking aspirin, and among those with CVD, 85.9% of men and 85.1% of women reported taking aspirin. Data on preventive use of aspirin by sociodemographic characteristics yielded mixed results.
format Online
Article
Text
id pubmed-5590489
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-55904892017-09-15 Aspirin for Prevention of Cardiovascular Disease Mendy, Vincent L. Vargas, Rodolfo Zhang, Lei Prev Chronic Dis Brief We used data from the 2013 Mississippi Behavioral Risk Factor Surveillance System to examine aspirin use for the prevention of primary and secondary cardiovascular disease (CVD), based on the 2009 US Preventive Services Task Force (USPSTF) guidelines, among Mississippi men (aged 45–79 y) and women (aged 55–79 y) and to explore differences in aspirin use by sociodemographic characteristics. Among those without CVD, 39.1% of men and 45.9% of women reported taking aspirin, and among those with CVD, 85.9% of men and 85.1% of women reported taking aspirin. Data on preventive use of aspirin by sociodemographic characteristics yielded mixed results. Centers for Disease Control and Prevention 2017-09-07 /pmc/articles/PMC5590489/ /pubmed/28880838 http://dx.doi.org/10.5888/pcd14.170171 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Brief
Mendy, Vincent L.
Vargas, Rodolfo
Zhang, Lei
Aspirin for Prevention of Cardiovascular Disease
title Aspirin for Prevention of Cardiovascular Disease
title_full Aspirin for Prevention of Cardiovascular Disease
title_fullStr Aspirin for Prevention of Cardiovascular Disease
title_full_unstemmed Aspirin for Prevention of Cardiovascular Disease
title_short Aspirin for Prevention of Cardiovascular Disease
title_sort aspirin for prevention of cardiovascular disease
topic Brief
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590489/
https://www.ncbi.nlm.nih.gov/pubmed/28880838
http://dx.doi.org/10.5888/pcd14.170171
work_keys_str_mv AT mendyvincentl aspirinforpreventionofcardiovasculardisease
AT vargasrodolfo aspirinforpreventionofcardiovasculardisease
AT zhanglei aspirinforpreventionofcardiovasculardisease